Loading
companiesCompany
Kura Oncology
Kura Oncology developed ziftomenib, the second menin inhibitor approved for leukaemia (November 2025), in partnership with Kyowa Kirin.
Overview
Kura Oncology, based in San Diego and listed as KURA, developed ziftomenib, the second menin inhibitor approved for leukaemia, in partnership with Kyowa Kirin. Ziftomenib, sold as Komzifti, was approved on 13 November 2025 for relapsed or refractory NPM1-mutated acute myeloid leukaemia on the KOMET-001 trial, the KOMET-007 trials test it with 7+3 chemotherapy and with venetoclax and azacitidine in frontline disease, and the company also has a farnesyl-transferase inhibitor programme; the global Kyowa Kirin partnership dates from 2024. OnCo links it to acute myeloid leukaemia and to the AUGMENT-101 paper on revumenib, the first menin inhibitor. Whether menin inhibitors move into first-line combinations is the question KOMET-007 will answer. The FDA approval notice is linked.
Headquarters
San Diego, CA, US
Scorecard
All companies#243of 1244 companies, score 21
- approved products +6
- targets +6
- modalities +2
- regions +1
- 24-month regulatory events +2
- registry trials +4
1 approved, 0 in phase 3, 0 earlier, 3 targets, 5 registry studies. Formula on the scorecards page.
Type
Biotech · KURA
Stage
Public
Website
ApprovedSmall-molecule menin inhibitor
Ziftomenib · Komzifti
Ziftomenib is the second menin inhibitor for leukaemia, approved in November 2025 as a once-daily pill for relapsed NPM1-mutated AML.
Similar pages
- PairingMenin inhibitor + venetoclax + azacitidine
Shares AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, Ziftomenib, Acute myeloid leukaemia.
- TargetNPM1 mutation
Shares KOMET-001, AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, Ziftomenib, Acute myeloid leukaemia.
- TrialA Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia
Shares Ziftomenib, Acute myeloid leukaemia.
- CompanySyndax Pharmaceuticals
Shares AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, Acute myeloid leukaemia.
- PersonGhayas C. Issa
Shares AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, Acute myeloid leukaemia.
- PersonEytan M. Stein
Shares AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, Acute myeloid leukaemia.
- CancerNPM1-mutated and KMT2A-rearranged acute myeloid leukaemia
Shares KOMET-001, Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML, AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, Ziftomenib.
- BiomarkerNPM1 mutation
Shares Ziftomenib, Acute myeloid leukaemia.